A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma
British Journal of Radiology · 2024
DOI: 10.1093/bjr/tqae025 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Chunmei Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Young Talent Program of China National Nuclear Corporation, Sichuan Science and Technology Innovation and Entrepreneurship Seedling, Natural Science Foundation of Chengdu Medical College.
Abstract (Originalsprache)
Objectives
As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison.
Methods
Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans.
Results
Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT.
Conclusions
These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results. Advances in knowledge Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Urology, Fushun People's Hospital, Zigong, Sichuan 643000, China.
- Department of Nuclear Medicine, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, Sichuan 610000, China.
ORCID-Profile: Zhanwen Huang
Förderung
- Young Talent Program of China National Nuclear Corporation
- Sichuan Science and Technology Innovation and Entrepreneurship Seedling
- Natural Science Foundation of Chengdu Medical College
- China Baoyuan Research Fund
- Sichuan Provincial Medical Youth Innovation Research
Zitieren
APA
Guo, C., Liu, Y., Yang, H., Xia, Y., Li, X., Chen, L., Feng, Y., Zhang, Y., Chen, Y., & Huang, Z. (2024). A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae025
Vancouver
Guo C, Liu Y, Yang H, Xia Y, Li X, Chen L, et al. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae025
BibTeX
@article{Guo2024,
author = {Guo, Chunmei and Liu, Ya and Yang, Haozhou and Xia, Yuxiao and Li, Xue and Chen, Liming and Feng, Yue and Zhang, Yan and Chen, Yue and Huang, Zhanwen},
title = {A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma},
journal = {British Journal of Radiology},
year = {2024},
doi = {10.1093/bjr/tqae025}
}
EUVIMED